A Phase 4 interventional study of Oxycodone/naloxone in Chronic Pain, sponsored by Mundipharma Korea Ltd. Completed at 1 site in Korea, Republic of. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2017-03-10.
Sponsored by Mundipharma Korea Ltd (part of Mundipharma) · Phase 4, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Chronic Pain with a site in Korea, Republic of — 10 open to participants now, 11 under way, none of them phase 3. Chronic Pain · Korea, Republic of.
Among the 36 studies in Chronic Pain with a site in Korea, Republic of, this one is the 4th largest by enrollment of the 28 interventional ones that give a count, is the only one that started in 2012, is one of 3 in phase 4, and was the 5th registered.
3,228 studies on the registry are indexed under Chronic Pain; 729 are open to participants now.
Browse Chronic Pain studies →10 of the 36 studies in Chronic Pain with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Jaseng Medical Foundation · Sites in Korea, Republic of
Ages 19–70
Korea University Guro Hospital · Sites in Korea, Republic of
Ages 19–79
Korea University · Sites in Korea, Republic of
Ages 60+ · Healthy volunteers
Keimyung University Dongsan Medical Center · Sites in Korea, Republic of
Ages 20–80
Sahmyook University · Sites in Korea, Republic of
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.
This study: 20 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 261 is above the median of 60 across 2,388 interventional studies indexed under Chronic Pain.
Median enrollment 76 across the 28 interventional studies, 89 across the 8 observational. Of the 17 that completed or were terminated, 5 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 36 have an industry lead sponsor. The 10 most frequent:
This study is registered under Mundipharma Korea Ltd, one of the names counted as Mundipharma. Under that name alone:
Mundipharma Korea Ltd is the lead sponsor of 16 studies on the registry; none are open to participants now.
Mundipharma has 9 studies filed under Chronic Pain — fewer than ten, so there is no comparison to draw.
4 of the studies in Chronic Pain with a site in Korea, Republic of that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06270121Sunmi SongDevelopment of a Healthcare Service Platform for Successful Aging | 2026-11-30 |
| NCT07832318Jaseng Medical FoundationEffectiveness and Safety of Pharmacopuncture Therapy for Chronic Lumbar Radiculopathy: A Multicenter, Pragmatic, Randomized, Comparative Clinical Trial | 2026-12 |
| NCT07917702Gwangju Health UniversityEffects of Transcranial Direct Current Stimulation and Manual Therapy on Musculoskeletal Pain in Adolescent Dancers | 2026-12-09 |
| NCT07485387Korea UniversityGlobal Collaborative Research on Establishing a Korean Cognitive Aging Cohort | 2027-04-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 36 studies in Chronic Pain with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Objectives:
Objective of main interest
Further objectives
Study Design (Methodology):
This will be a single center, open-label, randomised, phase IV, exploratory interventional study to compare the efficacy and tolerability of current titration patterns and slow titration pattern with Targin® (Oxycodone/Naloxone) in the treatment of moderate to severe non-malignant chronic pain patients who are dissatisfied with their current analgesic medication World Health Organisation (WHO) step II analgesics).
Upon providing written informed consent, subject will be screened in the study and assessment will be performed at that time such as safety laboratory assessments, physical examination, vital sign, medical history taking, 24 hours pain intensity score. If the patient is eligible in inclusion/exclusion criteria at the time of visit 1, the patient will be randomized in a 1:1 ratio to allocate in Group A or Group B. Re-screening, study drug dose interruption is not allowed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Start oxycodone/naloxone 10/5mg b.i.d. titration-\>20/10mg b.i.d.-\>30/15mg b.i.d-\>40/20mg b.i.d.
Drug: Oxycodone/naloxone
Start oxycodone/naloxone 5/2.5mg b.i.d titration-\> 10/5mg b.i.d.-\>20/10mg b.i.d.-\>30/15mg b.i.d-\>40/20mg b.i.d.
Drug: Oxycodone/naloxone
Drop-out Rate Caused by Adverse Event After 6 Weeks Treatment
To assess the drop-out rate caused by adverse event\* after 6 weeks treatment
Time frame: 6 weeks
The Drop-out Rate Due to an Adverse Event After 1 Week Treatment With the Study Drug.
The drop-out rate due to an adverse event after treatment (1 week) by treatment arm were summarized and presented as frequency and percentage, and the inter-group difference were compared by using a Chi-square test or Fisher's exact test.
Time frame: 1 week
The Change of Pain Intensity Scores(NRS) From Baseline After 6 Weeks Treatment With the Study.
Change in numeric rating scales (NRS) such as score for average pain levels over the previous 24 hours, from baseline to 6weeks. NRS score was measured from 0 (No pain) to 10(worst pain imaginable).
Time frame: 6 weeks
Change of Quality of Life (EQ-5D) Score After 6 Weeks Treatment With the Study Drug
EQ-5D to measure of health related quality of life should be answered as one of 3 levels about current condition for 5 dimensions and was calculated total average by giving a weighting on 3 level of answers (EQ-5D levels into 'no problems' (level 1) and 'problems' (level 2 and 3)). Table of scores by each level for EQ-5D items: mobility(level 1=0, level2=0.069,level 3=0.314), self care(level 1=0, level2=0.104,level 3=0.214), usual activities(level 1=0, level2=0.036,level 3=0.094), pain/discomfort (level 1=0, level2=0.,level 3=0.386) and anxiety/depression(level 1=0, level2=0.071,level 3=0.2) \*EQ-5D Total = 1 - 0.081 - (the score of the each level) - 0.269 (if at least one of level 3 presents) EQ-5D total score could be 0.919 in maximum and -0.594 in minimum if case all index indicates the level 3. So, if EQ-5D total score closed by "1" means that the healthy condition and high quality of life.
Time frame: 6 weeks
Assessment of Investigator's Overall Satisfaction After 6 Weeks Treatment With the Study Drug
Investigator's overall satisfaction after treatment (6 weeks) (Clinical Global Impression of Change Scale(CGIC) 7 point scale) by treatment arm were summarized and presented as frequency and proportion, and the inter-group difference were compared by using a Chi-square test or Fisher's exact test.
Time frame: 6 weeks
Assessment of Subject's Overall Satisfaction After 6 Weeks Treatment With the Study Drug
At each visit, the subject assessed the overall satisfaction for efficacy by using the 7 point scale of Patient Global Impression of Change Scale(PGIC).
Time frame: 6weeks
Safety set: 261 patients were enrolled. ITT set was 258, 3 patients of the 261 patients deviated from inclusion/exclusion criteria.
| Milestone | Start Oxycodone/Naloxone 10/5mg b.i.d. | Start Oxycodone/Naloxone 5/2.5mg b.i.d |
|---|---|---|
| Started | 132 | 126 |
| Completed | 61 | 64 |
| Not completed | 71 | 62 |
| Withdrew: Adverse event | 54 | 38 |
| Withdrew: Protocol violation | 5 | 6 |
| Withdrew: Withdrawal by subject | 5 | 10 |
| Withdrew: Lack of efficacy | 3 | 6 |
| Withdrew: Lost to follow-up | 4 | 2 |
To assess the drop-out rate caused by adverse event\* after 6 weeks treatment
| percentage of participants | Start Oxycodone/Naloxone 10/5mg b.i.d. | Start Oxycodone/Naloxone 5/2.5mg b.i.d. |
|---|---|---|
| Drop-out Rate Caused by Adverse Event After 6 Weeks Treatment | 40.91 | 30.16 |
The drop-out rate due to an adverse event after treatment (1 week) by treatment arm were summarized and presented as frequency and percentage, and the inter-group difference were compared by using a Chi-square test or Fisher's exact test.
| percentage of participants | Start Oxycodone/Naloxone 10/5mg b.i.d. | Start Oxycodone/Naloxone 5/2.5mg b.i.d. |
|---|---|---|
| The Drop-out Rate Due to an Adverse Event After 1 Week Treatment With the Study Drug. | 28.79 | 19.84 |
Change in numeric rating scales (NRS) such as score for average pain levels over the previous 24 hours, from baseline to 6weeks. NRS score was measured from 0 (No pain) to 10(worst pain imaginable).
| units on a scale | Start Oxycodone/Naloxone 10/5mg b.i.d. | Start Oxycodone/Naloxone 5/2.5mg b.i.d. |
|---|---|---|
| The Change of Pain Intensity Scores(NRS) From Baseline After 6 Weeks Treatment With the Study. | -1.62 ± 1.90 | -1.48 ± 1.82 |
EQ-5D to measure of health related quality of life should be answered as one of 3 levels about current condition for 5 dimensions and was calculated total average by giving a weighting on 3 level of answers (EQ-5D levels into 'no problems' (level 1) and 'problems' (level 2 and 3)). Table of scores by each level for EQ-5D items: mobility(level 1=0, level2=0.069,level 3=0.314), self care(level 1=0, level2=0.104,level 3=0.214), usual activities(level 1=0, level2=0.036,level 3=0.094), pain/discomfort (level 1=0, level2=0.,level 3=0.386) and anxiety/depression(level 1=0, level2=0.071,level 3=0.2) \*EQ-5D Total = 1 - 0.081 - (the score of the each level) - 0.269 (if at least one of level 3 presents) EQ-5D total score could be 0.919 in maximum and -0.594 in minimum if case all index indicates the level 3. So, if EQ-5D total score closed by "1" means that the healthy condition and high quality of life.
| units on a scale | Start Oxycodone/Naloxone 10/5mg b.i.d. | Start Oxycodone/Naloxone 5/2.5mg b.i.d. |
|---|---|---|
| Change of Quality of Life (EQ-5D) Score After 6 Weeks Treatment With the Study Drug | 0.14 ± 0.26 | 0.07 ± 0.22 |
Investigator's overall satisfaction after treatment (6 weeks) (Clinical Global Impression of Change Scale(CGIC) 7 point scale) by treatment arm were summarized and presented as frequency and proportion, and the inter-group difference were compared by using a Chi-square test or Fisher's exact test.
| participants | Start Oxycodone/Naloxone 10/5mg b.i.d | Start Oxycodone/Naloxone 5/2.5mg b.i.d |
|---|---|---|
| Very much improved | 2 | 2 |
| Much improved | 27 | 30 |
| Minimally improved | 48 | 43 |
| No change | 5 | 14 |
| Minimally worse | 0 | 0 |
| Much worse | 0 | 0 |
| very much worse | 0 | 0 |
At each visit, the subject assessed the overall satisfaction for efficacy by using the 7 point scale of Patient Global Impression of Change Scale(PGIC).
| participants | Start Oxycodone/Naloxone 10/5mg b.i.d. | Start Oxycodone/Naloxone 5/2.5mg b.i.d. |
|---|---|---|
| Very much improved | 2 | 2 |
| Much improved | 24 | 28 |
| Minimally improved | 44 | 42 |
| No change | 11 | 16 |
| Minimally worse | 0 | 1 |
| Much worse | 1 | 0 |
| Very much worse | 0 | 0 |
Collected over Safety set: Safety set included data obtained from all subjects who administered at least one dose of the study drug. Patients were followed by 6 weeks.. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Start Oxycodone/Naloxone 10/5mg b.i.d | — | 0/133 (0%) | 115/133 (86.5%) |
| Start Oxycodone/Naloxone 5/2.5mg b.i.d | — | 2/128 (1.6%) | 104/128 (81.3%) |
| Event | Start Oxycodone/Naloxone 10/5mg b.i.d | Start Oxycodone/Naloxone 5/2.5mg b.i.d |
|---|---|---|
| Duodenal stenosisGastrointestinal disorders | 0/133 | 1/128 |
| InflammationGeneral disorders | 0/133 | 1/128 |
| Femoral neck fractureInjury, poisoning and procedural complications | 0/133 | 1/128 |
| Event | Start Oxycodone/Naloxone 10/5mg b.i.d | Start Oxycodone/Naloxone 5/2.5mg b.i.d |
|---|---|---|
| NauseaGastrointestinal disorders | 52/133 | 46/128 |
| DizzinessNervous system disorders | 32/133 | 29/128 |
| SomnolenceNervous system disorders | 21/133 | 26/128 |
| vomitingGastrointestinal disorders | 27/133 | 16/128 |
| ConstipationGastrointestinal disorders | 24/133 | 21/128 |
| PruritusSkin and subcutaneous tissue disorders | 20/133 | 17/128 |
| HeadacheNervous system disorders | 15/133 | 8/128 |
| UrticariaSkin and subcutaneous tissue disorders | 7/133 | 0/128 |
| InsomniaPsychiatric disorders | 6/133 | 2/128 |
| DyspepsiaGastrointestinal disorders | 5/133 | 2/128 |
Safety set: 261 ITT set: 258(3 patients were deviated inclusion/exclusion criteria among 261)
| Age, Categorical(Participants) | Start Oxycodone/Naloxone 10/5mg b.i.d | Start Oxycodone/Naloxone 5/2.5mg b.i.d | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 77 | 64 | 141 |
| >=65 years | 55 | 62 | 117 |
| Age, Continuous(years) | Start Oxycodone/Naloxone 10/5mg b.i.d | Start Oxycodone/Naloxone 5/2.5mg b.i.d | Total |
|---|---|---|---|
| Mean | 60.63 ± 9.69 | 61.15 ± 11.94 | 60.88 ± 10.83 |
| Sex: Female, Male(Participants) | Start Oxycodone/Naloxone 10/5mg b.i.d | Start Oxycodone/Naloxone 5/2.5mg b.i.d | Total |
|---|---|---|---|
| Female | 81 | 84 | 165 |
| Male | 51 | 42 | 93 |
| Region of Enrollment(participants) | Start Oxycodone/Naloxone 10/5mg b.i.d | Start Oxycodone/Naloxone 5/2.5mg b.i.d | Total |
|---|---|---|---|
| Korea, Republic of | 132 | 126 | 258 |
Plan to share: No
No publications or documents are linked to this record.
The record gives a start of Dec 2012, a primary completion of Jan 2014 and a completion of Jun 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2017, 3 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Oxycodone · Naloxone